| 產(chǎn)品編號 | bs-3573R |
| 英文名稱 | Rabbit Anti-ADAMTS5 antibody |
| 中文名稱 | 軟骨蛋白聚糖抗體 |
| 別 名 | A disintegrin and metalloproteinase with thrombospondin motifs 5; A disintegrin like and metalloprotease (reprolysin type) with thrombospondin type 1 motif 5; A Disintigrin And Metalloproteinase with ThromboSpondin motif-5; ADAM metallopeptidase with thrombospondin type 1 motif 5; ADAM TS 11; ADAM TS 5; ADAM TS5; ADAMTS 11; ADAMTS 5; ADAMTS11; ADMP 2; ADMP2; Aggrecanase 2; aggrecanase-2; FLJ36738; Implantin; ThromboSpondin motif-5. |
 |
Specific References (23) | bs-3573R has been referenced in 23 publications.
|
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human,Mouse,Rat (predicted: Rabbit,Pig,Cow,Dog,Horse) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 102kDa |
| 細(xì)胞定位 | 細(xì)胞核 細(xì)胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human ADAMTS5 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
ADAMTS5 was first described as ADAMTS5, a protein elevated in mice during the peri-implantion period. At the same time, another group identified Aggrecanase 11, a protein elevated in arthritic synovium. The name was later changed to ADAMTS5. ADAMTS5 is expressed in human and mouse. It has been found in heart, lung, cervix, uterus, ovary, brain, cartilage, and numerous other tissues, as well as chondroblastoma cell lines. Initial observations indicated a role for ADAMTS5 in aggrecan cleavage and cartilage destruction, especially in arthritis, and potentially a role in embryo implantation. ADAMTS5 contains the canonical HExxHxxxxxH zinc metalloproteinase motif, and has been shown to efficiently cleave Aggrecan. In addition to the metalloprotease domain, ADAMTS5 has a propeptide domain, a prohormone convertase (PC, furin) cleavage site, a cysteine-rich domain, a spacer domain, and two thrombospondin-1 like domains. ADAMTS5 is inhibited by the endogenous MMP inhibitors (TIMP1, 2, 3, and 4) but most efficiently by TIMP3. Unlike many of the ADAMs proteases, ADAMTS5 does not have a transmembrane domain, and is a secreted protein. Full length ADAMTS5 is a 930 amino acid protein with a predicted molecular mass is 101.7 kDa, but glycosylation and the abundance of cysteine residues gives ADAMTS5 a greater apparent molecular weight on reduced SDS PAGE gels. When ADAMTS5 is secreted, it is cleaved at the furin cleavage site (predicted molecular mass 73.2 kDa) and then further cleaved to generate a range of smaller forms. Function: Cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. May play an important role in the destruction of aggrecan in arthritic diseases. May play a role in proteolytic processing mostly during the peri-implantation period. Subcellular Location: Secreted, extracellular space, extracellular matrix. Tissue Specificity: Expressed at low level in placenta primarily but also detected in heart and brain, cervix, uterus, bladder, esophagus, rib cartilage, chondroblastoma, fibrous tissue and a joint capsule from an arthritic patient. Post-translational modifications: The precursor is cleaved by a furin endopeptidase. C- and O-glycosylated. O-fucosylated by POFUT2 on a serine or a threonine residue found within the consensus sequence C1-X(2)-(S/T)-C2-G of the TSP type-1 repeat domains where C1 and C2 are the first and second cysteine residue of the repeat, respectively. Fucosylated repeats can then be further glycosylated by the addition of a beta-1,3-glucose residue by the glucosyltransferase, B3GALTL. Fucosylation can mediate the efficient secretion of ADAMTS family members. Can be C-glycosylated with one or two mannose molecules on tryptophan residues within the consensus sequence W-X-X-W of the TPRs, and N-glycosylated. These other glycosylations can also facilitate secretion. Glycosylated. Can be O-fucosylated by POFUT2 on a serine or a threonine residue found within the consensus sequence C1-X(2)-(S/T)-C2-G of the TSP type-1 repeat domains where C1 and C2 are the first and second cysteine residue of the repeat, respectively. Fucosylated repeats can then be further glycosylated by the addition of a beta-1,3-glucose residue by the glucosyltransferase, B3GALTL. Fucosylation mediates the efficient secretion of ADAMTS family members. Also can be C-glycosylated with one or two mannose molecules on tryptophan residues within the consensus sequence W-X-X-W of the TPRs, and N-glycosylated. These other glycosylations can also facilitate secretion. Similarity: Contains 1 disintegrin domain. Contains 1 peptidase M12B domain. Contains 2 TSP type-1 domains. SWISS: Q9UNA0 Gene ID: 11096 Database links: Entrez Gene: 11096 Human Entrez Gene: 23794 Mouse Omim: 605007 Human SwissProt: Q9UNA0 Human SwissProt: Q9R001 Mouse Unigene: 58324 Human Unigene: 112933 Mouse |
| 產(chǎn)品圖片 |
Sample:
Lane 1: Mouse Placenta tissue lysates
Lane 2: Mouse Spleen tissue lysates
Lane 3: Human U87MG cell lysates
Lane 4: Human U251 cell lysates
Lane 5: Human SH-SY5Y cell lysates
Lane 6: Human HeLa cell lysates
Primary: Anti- ADAMTS5 (bs-3573R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 102 kDa
Observed band size: 102 kDa
Tissue/cell: rat brain tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-Aggrecanase-2/ADAMTS5 Polyclonal Antibody, Unconjugated(bs-3573R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|
